Prospective Trial of Minimal Residual Disease Assessment by Multiparametric Flow Cytometry for Multiple Myeloma in the Era of Bortezomib-Based Chemotherapy
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2017.12.088
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2018
Authors
Publisher
Elsevier BV